(UroToday.com) The 2025 GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Xinan Sheng discussing the phase II RC48-C017 trial assessing neoadjuvant treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results